| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 76.75▼ | 76.75▼ | 76.75▼ | 76.90▼ | 76.67▲ |
| MA10 | 76.82▼ | 76.82▼ | 76.82▼ | 76.80▼ | 76.28▲ |
| MA20 | 76.83▼ | 76.83▼ | 76.83▼ | 76.61▲ | 76.39▲ |
| MA50 | 76.73▼ | 76.63▲ | 76.57▲ | 76.18▲ | N/A |
| MA100 | 76.39▲ | 76.32▲ | 76.26▲ | 76.45▲ | N/A |
| MA200 | 76.16▲ | 76.15▲ | 76.25▲ | N/A | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.034▼ | -0.040▼ | -0.043▼ | 0.003▲ | 0.095▲ |
| RSI | 41.903▼ | 44.526▼ | 45.755▼ | 55.190▲ | 58.424▲ |
| STOCH | 3.590▼ | 3.980▼ | 3.980▼ | 64.681 | 71.597 |
| WILL %R | -100.000▼ | -100.000▼ | -100.000▼ | -65.789 | -29.586 |
| CCI | -114.413▼ | -114.002▼ | -114.002▼ | -13.503 | 104.909▲ |
|
Wednesday, December 10, 2025 05:00 AM
GERMANTOWN, Md., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), an immunology and inflammation (“I&I”) company focused on ...
|
|
Wednesday, December 10, 2025 12:00 AM
VTP-1000, an antigen-specific immunotherapy to treat celiac disease, showed a dose-dependent pharmacological effect in the SAD portion of the trial VTP-1000 was well-tolerated with no ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 04/03/26 | 76.80 | 76.80 | 76.69 | 76.69 | 41,526 |
| 03/03/26 | 76.72 | 76.899 | 76.67 | 76.83 | 16,684 |
| 02/03/26 | 77.09 | 77.09 | 76.75 | 76.91 | 16,100 |
| 27/02/26 | 77.19 | 77.19 | 77.04 | 77.0704 | 20,237 |
| 26/02/26 | 76.89 | 76.99 | 76.84 | 76.99 | 16,862 |
| 25/02/26 | 76.63 | 76.82 | 76.63 | 76.78 | 24,800 |
| 24/02/26 | 76.685 | 76.73 | 76.635 | 76.73 | 16,000 |
| 23/02/26 | 76.71 | 76.80 | 76.65 | 76.72 | 13,800 |
| 20/02/26 | 76.68 | 76.68 | 76.52 | 76.63 | 14,400 |
| 19/02/26 | 76.53 | 76.70 | 76.53 | 76.69 | 20,400 |
|
|
||||
|
|
||||
|
|